vs
Esperion Therapeutics, Inc.（ESPR）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是Esperion Therapeutics, Inc.的1.1倍（$188.3M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -21.9%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -15.4%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
ESPR vs RILY — 直观对比
营收规模更大
RILY
是对方的1.1倍
$168.4M
营收增速更快
ESPR
高出165.6%
-21.9%
两年增速更快
ESPR
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $188.3M |
| 净利润 | — | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | 50.6% | 32.3% |
| 净利率 | — | 47.9% |
| 营收同比 | 143.7% | -21.9% |
| 净利润同比 | — | 1710.8% |
| 每股收益（稀释后） | $0.32 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRRILY
| Q4 25 | $168.4M | $188.3M | ||
| Q3 25 | $87.3M | $215.3M | ||
| Q2 25 | $82.4M | $188.2M | ||
| Q1 25 | $65.0M | $197.2M | ||
| Q4 24 | $69.1M | $241.0M | ||
| Q3 24 | $51.6M | $225.5M | ||
| Q2 24 | $73.8M | $256.0M | ||
| Q1 24 | $137.7M | $263.4M |
净利润ESPRRILY
| Q4 25 | — | $90.3M | ||
| Q3 25 | $-31.3M | $91.1M | ||
| Q2 25 | $-12.7M | $139.5M | ||
| Q1 25 | $-40.5M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-29.5M | $-284.4M | ||
| Q2 24 | $-61.9M | $-433.6M | ||
| Q1 24 | $61.0M | $-49.2M |
毛利率ESPRRILY
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率ESPRRILY
| Q4 25 | 50.6% | 32.3% | ||
| Q3 25 | -11.4% | 30.4% | ||
| Q2 25 | 8.6% | 5.7% | ||
| Q1 25 | -34.0% | -31.2% | ||
| Q4 24 | -6.4% | -69.2% | ||
| Q3 24 | -31.0% | -36.4% | ||
| Q2 24 | 3.5% | -90.8% | ||
| Q1 24 | 52.5% | -6.1% |
净利率ESPRRILY
| Q4 25 | — | 47.9% | ||
| Q3 25 | -35.9% | 42.3% | ||
| Q2 25 | -15.4% | 74.1% | ||
| Q1 25 | -62.2% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -57.2% | -126.1% | ||
| Q2 24 | -83.9% | -169.4% | ||
| Q1 24 | 44.3% | -18.7% |
每股收益（稀释后）ESPRRILY
| Q4 25 | $0.32 | $2.78 | ||
| Q3 25 | $-0.16 | $2.91 | ||
| Q2 25 | $-0.06 | $4.50 | ||
| Q1 25 | $-0.21 | $-0.39 | ||
| Q4 24 | $-0.14 | $-0.01 | ||
| Q3 24 | $-0.15 | $-9.39 | ||
| Q2 24 | $-0.33 | $-14.35 | ||
| Q1 24 | $0.34 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $-302.0M | $-171.5M |
| 总资产 | $465.9M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRRILY
| Q4 25 | $167.9M | $226.6M | ||
| Q3 25 | $92.4M | $184.2M | ||
| Q2 25 | $86.1M | $267.4M | ||
| Q1 25 | $114.6M | $138.3M | ||
| Q4 24 | $144.8M | $146.9M | ||
| Q3 24 | $144.7M | $159.2M | ||
| Q2 24 | $189.3M | $236.9M | ||
| Q1 24 | $226.6M | $190.7M |
总债务ESPRRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ESPRRILY
| Q4 25 | $-302.0M | $-171.5M | ||
| Q3 25 | $-451.4M | $-260.5M | ||
| Q2 25 | $-433.5M | $-351.7M | ||
| Q1 25 | $-426.2M | $-496.8M | ||
| Q4 24 | $-388.7M | $-488.2M | ||
| Q3 24 | $-370.2M | $-497.6M | ||
| Q2 24 | $-344.2M | $-218.3M | ||
| Q1 24 | $-294.3M | $228.4M |
总资产ESPRRILY
| Q4 25 | $465.9M | $1.7B | ||
| Q3 25 | $364.0M | $1.7B | ||
| Q2 25 | $347.1M | $1.5B | ||
| Q1 25 | $324.0M | $1.5B | ||
| Q4 24 | $343.8M | $1.8B | ||
| Q3 24 | $314.1M | $2.2B | ||
| Q2 24 | $352.3M | $3.2B | ||
| Q1 24 | $373.1M | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRRILY
| Q4 25 | $45.2M | $26.2M | ||
| Q3 25 | $-4.3M | $-60.6M | ||
| Q2 25 | $-31.4M | $-25.6M | ||
| Q1 25 | $-22.6M | $184.0K | ||
| Q4 24 | $-35.0M | $-2.7M | ||
| Q3 24 | $-35.3M | $19.5M | ||
| Q2 24 | $-7.2M | $111.5M | ||
| Q1 24 | $53.8M | $135.4M |
自由现金流ESPRRILY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
自由现金流率ESPRRILY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
资本支出强度ESPRRILY
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
现金转化率ESPRRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
